Coronary atherosclerosis: current therapeutic approaches and future trends
Related Experiment Videos
1Institute for BioScience, Grafton, MA 01519.
Insights
New therapies are needed to manage restenosis after procedures like angioplasty. Targeting cellular proliferation and promoting endothelial regrowth offers promising strategies for cardiovascular disease treatment.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Pharmacology
Background:
- Atherectomy and bypass surgery are key treatments for coronary heart disease (CHD).
- Vascular injury from these procedures causes intimal hyperplasia, leading to restenosis.
- Current drugs are ineffective for managing post-procedural stenosis.
Purpose of the Study:
- To review existing drug therapies for restenosis.
- To explore novel therapeutic approaches for preventing restenosis.
- To identify key molecular targets for future drug development.
Main Methods:
- Literature review of current and emerging treatments for restenosis.
- Discussion of growth factors and cellular responses involved in intimal hyperplasia.
- Analysis of potential therapeutic agents, including growth factors and modified existing drugs.
Main Results:
- Existing drug therapies for restenosis are limited.
- Inhibiting cellular proliferation and promoting endothelial regrowth are promising strategies.
- Growth factors like PDGF, bFGF, EDRF, and CGRP are key targets.
Conclusions:
- Novel therapeutic strategies are required to combat restenosis.
- Targeting the cellular proliferative response and endothelial repair is crucial.
- Further research into growth factors and drug modification holds potential for effective restenosis treatment.
Abstract:
Invasive cardiovascular procedures, such as percutaneous translumenal coronary angioplasty (PTCA) and aorto-coronary bypass surgery (ACBS), that are currently employed in treating the coronary stenosis or occlusion caused by atherosclerosis represent a major therapeutic advance for managing coronary heart disease (CHD). However, the cellular proliferative response and associated intimal hyperplasia that can follow the damage to blood vessels that occurs with these procedures leads to late complications which cannot be effectively controlled by presently available drugs. Hence, a new approach is required for managing these complications, termed "restenosis" (in the case of PTCA) or "stenosis" (in the case of ACBS). Existing drug therapy is reviewed and some new approaches to this problem are provided herein. Further studies of growth factors and other substances that influence the cellular proliferative response that follows injury to the blood vessel wall could lead to the development of effective therapy. Inhibition of intimal hyperplasia and/or acceleration of endothelial cell re-growth provide a basis for such new approaches. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), as well as endothelium-derived relaxing factor(s) (EDRF) and calcitonin gene-related peptide (CGRP) are among the substances discussed. Modification of certain currently available drugs (e.g. Ca(2+)-antagonists) could also be of value in meeting this therapeutic demand.